Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

This phase I trial studies the side effects and best dose of mocetinostat when given together with vinorelbine to see how well it works in treating children, adolescents, and young adults with

cancer chemotherapy
nervous
measurable disease
metastasis
cancer
  • 0 views
  • 14 Mar, 2022
  • 1 location
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined with Vinorelbine as third-line and posterior line treatment in patients with NSCLC

  • 0 views
  • 21 Aug, 2021
  • 1 location
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

The purpose of this multi-center,single arm,phase clinical trail is to determine the safety and efficacy of GVDR (gemcitabine, oral vinorelbine and doxorubicin liposome, with or without

doxorubicin
rituximab
gemcitabine
cell transplantation
b-cell lymphoma
  • 13 views
  • 15 Feb, 2022
  • 1 location
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC

This is a phase I, single arm, open-label trial that will utilise a Time To Event Continual Reassessment Method (TiTE-CRM) to determine the maximum tolerated dose (MTD) of atovaquone in combination with concurrent CRT in NSCLC. Twenty evaluable participants will be recruited at two centres.

  • 0 views
  • 29 Dec, 2021
  • 2 locations
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer

The primary objective is to compare docetaxel plus cisplatin (DP) versus vinorelbine plus cisplatin (NP) in neoadjuvant chemoradiotherapy, in terms of the overall survival and toxicity in

chemoradiotherapy
ivor
esophageal carcinoma
blood count
esophagectomy
  • 15 views
  • 24 Jan, 2021
  • 1 location
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of

bisphosphonate
her2/neu-negative breast cancer
mammogram
estrogen
hormone therapy
  • 0 views
  • 05 May, 2022
  • 60 locations
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301)

vedotin. Participants in the other group will get one of four different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, or irinotecan). Participants and their doctors will know which group they

metastatic cervical cancer
adenocarcinoma
treatment regimen
carboplatin
tisotumab vedotin
  • 3 views
  • 18 May, 2022
  • 65 locations
Vinorelbine for Recurrent ALCL-2017

The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.

stem cell transplantation
cancer
  • 6 views
  • 26 Feb, 2022
  • 1 location
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

) + Vinorelbine (Navelbine) Group B: Trastuzumab + Vinorelbine + Avelumab Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)

herceptin
immunostimulant
breast adenocarcinoma
pertuzumab
measurable disease
  • 30 views
  • 19 Apr, 2022
  • 14 locations
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

This is a proof-of-concept study to define efficacy of vinorelbine, cisplatin, disulfiram and copper in CTC_EMT positive refractory metastatic hormone receptor positive, HER2 negative breast

liver metastasis
growth factor
kidney function tests
bone metastases
hormone therapy
  • 37 views
  • 26 Feb, 2022
  • 1 location